Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTRECAMCT-01 perioperative SHR-A1811 plus camrelizumab vs conventional neoadjuvant chemotherapy in HER2-low, ER-low early/locally advanced breast cancer
ChiCTR2600127200Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab and camrelizumab in breast cancer (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Pathological complete remission rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trastuzumabcamrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600127200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127200.